Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00

Keros Therapeutics (NASDAQ:KROS) had its target price cut by Wells Fargo & Company from $28.00 to $26.00 in a report published on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock.

Other equities research analysts have also issued reports about the stock. TD Cowen lowered shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. BTIG Research cut Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 12th. Scotiabank cut their price target on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating for the company in a research note on Thursday, January 16th. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Finally, Oppenheimer reduced their target price on shares of Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $42.33.

Keros Therapeutics Price Performance

Keros Therapeutics stock opened at $11.01 on Thursday. Keros Therapeutics has a one year low of $9.77 and a one year high of $73.00. The business’s fifty day moving average is $12.64 and its 200 day moving average is $39.79. The stock has a market capitalization of $445.98 million, a PE ratio of -2.11 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.22. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $3.04 million for the quarter, compared to the consensus estimate of $37.32 million. As a group, sell-side analysts expect that Keros Therapeutics will post -4.74 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Braidwell LP lifted its position in shares of Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after acquiring an additional 1,187,199 shares in the last quarter. Point72 Asset Management L.P. raised its stake in Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after purchasing an additional 577,220 shares during the period. Lynx1 Capital Management LP purchased a new position in Keros Therapeutics in the 4th quarter worth approximately $8,612,000. Millennium Management LLC boosted its stake in Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock worth $13,901,000 after purchasing an additional 305,169 shares during the period. Finally, Alkeon Capital Management LLC grew its holdings in Keros Therapeutics by 18.7% during the 3rd quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.